European Schizophrenia Drugs Market Growth, Size, Share and Forecast 2020-2026

The European schizophrenia drug market is projected to grow at a significant CAGR of around 2.5% during the forecast period (2020-2026). The availability of considerable resources for mental health and a sophisticated healthcare system are other key factors that are expected to promote the growth of the market. In the UK, Mental Health First Aid (MHFA) England, a social organization that offers expert guidance and training to support mental health, estimated in 2019 that nearly one in four people face mental health issues each year and are responsible for 72 million working days lost and costs $45.5 billion each year. Therefore, a significant market is estimated in Europe for schizophrenia drugs.

A full report of European Schizophrenia Drugs Market is available at: https://www.omrglobal.com/industry-reports/european-schizophrenia-drugs-market

Further, according to the WHO, almost 83 million people are affected annually by mental disorders among the adult population of Europe (aged 18-65), where female rates are higher than males. This involves the high demand for products which can bring down the level of schizophrenia among people. According to the Institute for Health Metrics and Evaluation (IHME), the EU spent an average of $22 per capita on mental health programs and services in 2016. Nearly all the countries in the European region had a stand-alone or integrated mental health policy or plan. This can be considered as another factor for the substantial growth of the market in the region.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/european-schizophrenia-drugs-market

Market Coverage

• The market number available for – 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segments Covered
o By Therapeutic Class
o By Treatment
• Countries Covered
o UK
o Germany
o France
o Spain
o Italy
o RoE
• Allergan PLC, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc.

Key questions addressed by the report

• What is the market growth rate during the forecast period?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market during the forecast period?
• How COVID-19 will impact the market growth in 2020 and coming years?
o Recovery Timeline
o Deviation from pre-COVID-19
o Most affected region/segment
o Recommendations
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/european-schizophrenia-drugs-market

European Schizophrenia Drugs Market – Segmentation

By Therapeutic Class

• Second Generation Antipsychotics
• Third Generation Antipsychotics
• Others (First Generation Antipsychotics)

By Treatment

• Oral
• Injectables

European Schizophrenia Drugs Market – Segmentation by Geography

• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Company Profiles

• Alkermes PLC
• Allergan PLC
• AstraZeneca PLC
• Biogen, Inc.
• Eli Lilly and Co.
• H. Lundbeck A/S
• Johnson & Johnson Services, Inc.
• Lupin,Ltd.
• Merck & Co., Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com

This release was published on openPR.